LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 8.17% | 25.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.17% | 25.37% | |||
| Cost of Revenue | 10.57% | 20.60% | |||
| Gross Profit | 2.61% | 38.05% | |||
| SG&A Expenses | 6.27% | 23.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.44% | 23.65% | |||
| Operating Income | -14.45% | 66.43% | |||
| Income Before Tax | -48.39% | -105.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -48.39% | -105.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.39% | -105.90% | |||
| EBIT | -14.45% | 66.43% | |||
| EBITDA | 9.52% | 94.18% | |||
| EPS Basic | -50.00% | -105.78% | |||
| Normalized Basic EPS | -50.00% | 23.08% | |||
| EPS Diluted | -50.00% | -106.20% | |||
| Normalized Diluted EPS | -50.00% | 23.08% | |||
| Average Basic Shares Outstanding | 0.00% | -0.34% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||